Appraising Adjuvant Endocrine Therapy in Hormone Receptor Positive HER2-Negative Breast Cancer—A Literature Review

Background: Approximately 75% of breast cancer (BC) is associated with luminal differentiation expressing endocrine receptors (ER). For ER+ HER2− tumors, adjuvant endocrine therapy (ET) is the cornerstone treatment. Although relapse events steadily continue, the ET benefits translate to dramatically...

Descripción completa

Detalles Bibliográficos
Autores principales: Mata, Danilo Giffoni de Mello Morais, Amir Carmona, Carlos, Eisen, Andrea, Trudeau, Maureen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9320044/
https://www.ncbi.nlm.nih.gov/pubmed/35877254
http://dx.doi.org/10.3390/curroncol29070394

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9320044/
https://www.ncbi.nlm.nih.gov/pubmed/35877254
http://dx.doi.org/10.3390/curroncol29070394

Ejemplares similares